ALS News Today

Masitinib trial insurance offers a safety net for ALS research

Masitinib is an experimental oral therapy for ALS that's aimed at slowing disease progression. AB Science secured insurance ...
Business Insider

AB Science announced that the Food and Drug Administration (FDA) granted the status of ...

AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS PERSPECTIVE OF THE ANIMAL ...
Seeking Alpha

Stonegate Capital Partners Initiates Coverage on AB Science S.A. (AB)

Dallas, Texas--(Newsfile Corp. - February 10, 2026) - AB Science S.A. (ENXTPA: AB): Stonegate Capital Partners Initiates Coverage on AB Science S.A. (ENXTPA: AB). AB Science is a late-stage biotech ...
Reuters

AB Science: Masitinib receives orphan drug designation in EU for ALS

* Announces that Masitinib receives from European Medicines Agency (EMA) orphan drug designation in the European Union for Amyotrophic Lateral Sclerosis (ALS) Source text for Eikon: Further company ...